FDA OKs Opdivo for bladder cancer

The Food and Drug Administration approved Bristol-Myers Squibb’s best-selling cancer drug Opdivo to treat urothelial carcinoma — the most common type of bladder cancer, reports Reuters.

Advertisement

Opdivo is already approved to treat advanced forms of melanoma, non-small cell lung cancer, kidney cancer and Hodgkin’s lymphoma.

Bladder cancer is the fifth most commonly diagnosed cancer in the U.S., with about 77,000 new diagnoses and more than 16,000 deaths in 2016, according to news release.

More articles on supply chain:

This week’s 5 must-reads for supply chain leaders
A new framework for measuring the true value of drugs: 5 takeaways
Bloomberg: Medtronic arranging sale of medical supplies business

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.